Fake malaria drugs a growing problem: experts

by Kerry Sheridan

Fake or poor quality malaria drugs are boosting resistance in parts of southeast Asia, a problem that is likely to worsen unless tighter regulations are adopted, US experts said Monday.

"The has a history of adapting to drugs and adapting to insecticides," Regina Rabinovich, director of infectious diseases at the , told a hearing of US lawmakers.

" to the most effective drug available, artemisinin-based combination therapy, is developing and has been recognized in southeast Asia."

Last month, the said resistance to artemisinin appeared to be spreading in the region from the Cambodia-Thailand border, where it was first detected in 2009, and possibly moving into Myanmar.

Half of the world's population is exposed to the mosquito-borne disease which kills 860,000 people every year, according to the WHO.

According to Roger Bate of the American Enterprise Institute, research has shown that about half the that failed quality control tests also contained some artemisinin.

"So they are directly contributing to resistance," he told lawmakers at the House subcommitee on Africa, Global Health, and Human Rights.

"Resistance is being noticed on the Thai, Cambodian, Burmese borders and resistance is likely to increase," he said.

"Fake and substandard antimalarial medications are a significant and probably growing problem."

While the actual number of poor quality drugs in circulation is unknown, "it is certainly not a negligible amount," he added, and the problem is festering because these medications are not illegal in the countries affected.

"Simply getting the medical regulatory authorities to control what is on the market for anti malarials I think is important," said Bate.

The sale and use of monotherapies, which contain just one active agent, have long been known to contribute to resistance. Experts favor combination therapies which last longer.

Bate said that coordinated action to get monotherapies off the market in Africa has shown some success, "but some companies in China, India and Vietnam are still producing them and this is a major contribution to resistance."

In addition to tougher regulations, researchers need to focus on developing new drugs against malaria, and consider making sure they cannot be sold or distributed as monotherapies, the panelists urged.

"The goal now going forward is the new drugs we develop need to be made as fixed dose combinations immediately, and never be sold or available as single entities," said Dennis Schmatz, president of Medicines for Malaria Venture North America, Inc.

"And that will definitely extend the life of any of those new drugs we develop going forward."

Rabinovich echoed that point, saying that the drugs of today will not be effective tomorrow.

"Research and development is essential because the preventive and curative tools that are available today and are so effective at controlling malaria are not sufficient to control malaria in the long term or for eradication due in part to the development of resistance," she said.

add to favorites email to friend print save as pdf

Related Stories

Bad malaria pills in Africa raise resistance fears

Feb 08, 2010

(AP) -- High rates of the most effective type of malaria-fighting drugs sold in three African countries are poor quality - including nearly half the pills sampled in Senegal - raising fears of increased drug resistance that ...

Drug-resistant malaria has emerged in Cambodia

Jul 29, 2009

(PhysOrg.com) -- Malaria parasites in western Cambodia have become resistant to artemisinin-based therapies, the first-line treatment for malaria, according to a study published in the New England Journal of ...

Recommended for you

Xtoro approved for swimmer's ear

23 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

23 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.